Mevalonate pathway activation in Ewing sarcoma reveals a 3D-specific synergy between statins and BCL-xL inhibition
Molecular Therapy Oncology · 2026-06 · 34 (2) · 201229
DOI: 10.1016/j.omton.2026.201229 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy Oncology, 2026-06. Verfasst von Branka Radic-Sarikas und 10 weiteren Autor:innen. Beteiligte Einrichtung: St. Anna Children's Cancer Research Institute (CCRI), 1090 Vienna, Austria. Die Arbeit nennt 88 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Austrian Science Fund, Bundesministerium Bildung, Universiteit Gent.
Abstract (Originalsprache)
Bone sarcomas are rare and aggressive pediatric cancers with limited progress in targeted therapy development, partly due to the poor physiological relevance of conventional two-dimensional (2D) culture systems used for preclinical testing. To address this gap, we developed a standardized three-dimensional (3D) culture and drug-testing platform for Ewing sarcoma (ES) and osteosarcoma (OS) that more accurately recapitulates in vivo tumor biology. Notably, gene-expression analyses demonstrated that ES and OS spheroids transcriptionally converge toward patient tumor cell states, underscoring their physiological relevance for preclinical testing. Across 3D spheroids, bioprinted constructs, and patient-derived xenograft (PDX) cultures, we observed a consistent activation and dependency on the mevalonate pathway in ES. Leveraging this platform, we identified a selective therapeutic synergy between statins, which inhibit mevalonate pathway flux, and BCL-xL inhibitors-a vulnerability not detectable in 2D cultures. Importantly, this synergistic interaction was tumor-specific and absent in non-malignant fibroblasts, indicating a favorable therapeutic window. Together, these findings highlight the mevalonate pathway as a targetable metabolic dependency in ES and demonstrate how physiologically grounded 3D models can uncover clinically actionable treatment strategies that remain hidden in traditional 2D systems.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- St. Anna Children's Cancer Research Institute (CCRI), 1090 Vienna, Austria.
- Department of Pediatric and Adolescent Surgery, Medical University of Vienna, 1090 Vienna, Austria.
- Institute of Materials Science and Technology, Technische Universität Wien (TU Wien), 1040 Vienna, Austria.
- Austrian Cluster for Tissue Regeneration, Vienna, Austria.
- Zebrafish Platform Austria for Preclinical Drug Screening (ZANDR), 1090 Vienna, Austria.
- Inserm U830, Équipe Labellisée INCC, PSL Université, SIREDO Oncology Centre, Institut Curie, Paris, France.
Förderung
- Austrian Science Fund
- Bundesministerium Bildung
- Universiteit Gent
- Austrian Research Promotion Agency
Zitieren
APA
Radic-Sarikas, B., Markovic, M., Zylka, M. M., Sturtzel, C., Ilg, M., Surdez, D., Metzelder, M., Distel, M., Ovsianikov, A., Halbritter, F., & Kovar, H. (2026). Mevalonate pathway activation in Ewing sarcoma reveals a 3D-specific synergy between statins and BCL-xL inhibition. Molecular Therapy Oncology, 34(2), 201229. https://doi.org/10.1016/j.omton.2026.201229
Vancouver
Radic-Sarikas B, Markovic M, Zylka MM, Sturtzel C, Ilg M, Surdez D, et al. Mevalonate pathway activation in Ewing sarcoma reveals a 3D-specific synergy between statins and BCL-xL inhibition. Molecular Therapy Oncology. 2026;34(2):201229. doi:10.1016/j.omton.2026.201229
BibTeX
@article{RadicSarikas2026,
author = {Radic-Sarikas, Branka and Markovic, Marica and Zylka, Martha Magdalena and Sturtzel, Caterina and Ilg, Mathias and Surdez, Didier and Metzelder, Martin and Distel, Martin and Ovsianikov, Aleksandr and Halbritter, Florian and Kovar, Heinrich},
title = {Mevalonate pathway activation in Ewing sarcoma reveals a 3D-specific synergy between statins and BCL-xL inhibition},
journal = {Molecular Therapy Oncology},
year = {2026},
volume = {34},
number = {2},
pages = {201229},
doi = {10.1016/j.omton.2026.201229}
}
EUVIMED